A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Official Title
-----------------
Registry-based Non-interventional Analysis of Advanced/Metastatic Renal Carcinoma Treatment Patterns and Outcomes in the Hospital District of Southwest Finland.

Conditions
-----------------
Cancer of Kidney, Renal Cell Cancer, Renal Cell Carcinoma, Cancer of the Kidney, Kidney Cancer, Kidney Neoplasms, Renal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For the characteristic group: Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision [ICD]-10:64) during 01 January 2010 and 31 December 2021 For the mRCC group: ICD-10 diagnosis code for metastasis (C77*-C79*), or American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease Initiation of treatment for mRCC Exclusion Criteria: For the characteristic group: Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010) Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021 For the mRCC group: Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010) Patients without treatment for mRCC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographical Characteristics of Participants (treated) |  | During post-index period (January 2010 - December 2021) | 
| Demographical Characteristics of Participants (non-treated) |  | During post-index period (January 2010 - December 2021) | 
| International Metastatic Database Consortium (IMDC) Risk Group Status at Initiation of Treatment (treated) |  | During post-index period (January 2010 - December 2021) | 
| IMDC Risk Group Status at Initiation of Treatment (non-treated) |  | During post-index period (January 2010 - December 2021) | 
| Number of Treatments Received in the Advanced/Metastatic Renal Cell Carcinoma (mRCC) Setting |  | During post-index period (January 2010 - December 2021) | 
| Number of Treatment Sequences Received in the mRCC Setting |  | During post-index period (January 2010 - December 2021) | 
| Time to next treatment (TTNT) |  | During post-index period (January 2010 - December 2021) | 
| Overall Survival (OS) |  | During post-index period (January 2010 - December 2021) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Morbidities with Metastatic RCC |  | During post-index period (January 2010 - December 2021) | 
| Healthcare Resource Utilization |  | During post-index period (January 2010 - December 2021) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nivolumab, Advanced/ metastatic RCC (mRCC), Real World Evidence, Registry based study, Non-interventional study, Axitinib, Sunitinib, Pazopanib, Cabozantinib, Sorafenib, Everolimus, Ipilimumab